Sarcopenia

Decoding Sarcopenia: Advances in Research and Management: Dive into the evolving landscape of sarcopenia research. From cutting-edge studies on its impact on cancer patients to innovative management strategies, gain insights into combating this muscle-wasting condition.

Do myokines influence the associations between sarcopenia-related parameters and cognitive function in community-dwelling older adults: exploratory results from the ENHANce study.

BACKGROUND

Studies have shown that sarcopenia and its related parameters are associated with cognition. Preclinical evidence suggests that myokines, such as irisin, Brain-Derived Neurotrophic Factor(BDNF), myostatin and Insulin-like Growth Factor-1(IGF-1) might explain this relationship. This study aimed to explore the associations...

🗓️ 2026-01-19
📰 Publication: Experimental Gerontology
Read MoreDo myokines influence the associations between sarcopenia-related parameters and cognitive function in community-dwelling older adults: exploratory results from the ENHANce study.

HQ8: Do Nutritional Interventions Prevent the Onset and Progression of Frailty in Older Adults?: English Translation of the Japanese Guideline for Digital Health for the Prevention and Improvement of Sarcopenia and Frailty.

🗓️ 2026-01-15
📰 Publication: Geriatrics & Gerontology International
Read MoreHQ8: Do Nutritional Interventions Prevent the Onset and Progression of Frailty in Older Adults?: English Translation of the Japanese Guideline for Digital Health for the Prevention and Improvement of Sarcopenia and Frailty.

Screening for Malnutrition, Sarcopenia, and Physical Frailty Beyond One Year after Liver Transplantation.

BACKGROUND/AIMS

Malnutrition, sarcopenia, and frailty negatively impact quality of life and increase mortality following liver transplantation (LT). However, long-term follow-up data remain limited. This study aimed primarily to assess the malnutrition risk at 1-, 2-, and 3-years post-LT. Secondary objectives included...

🗓️ 2026-01-15
Read MoreScreening for Malnutrition, Sarcopenia, and Physical Frailty Beyond One Year after Liver Transplantation.

Can a consumer-grade bioimpedance device accurately estimate sarcopenia in women with type 2 diabetes? A cross-sectional agreement study with dual-energy X-ray absorptiometry.

AIMS

To evaluate the diagnostic performance of a consumer-grade bioelectrical impedance analyzer (OMRON HBF-514C) against dual-energy X-ray absorptiometry (DXA) for detecting sarcopenia in women with type 2 diabetes (T2DM).

METHODS

In this cross‑sectional study, 103 women with T2DM underwent body composition assessment using...

🗓️ 2025-12-24
📰 Publication: Diabetes Research And Clinical Practice
Read MoreCan a consumer-grade bioimpedance device accurately estimate sarcopenia in women with type 2 diabetes? A cross-sectional agreement study with dual-energy X-ray absorptiometry.

Public Health.

BACKGROUND

Sarcopenia is associated with an increased risk of cognitive impairment, yet very few studies have examined structural brain changes in sarcopenia. The current study aims to explore cognitive changes and their neuroimaging correlates of individuals with sarcopenia in an urban...

🗓️ 2025-12-23
📰 Publication: Alzheimers & Dementia
Read MorePublic Health.

Underweight and Mortality in Type 2 Diabetes: A Nationwide Retrospective Cohort Study.

BACKGROUND

Being underweight is an underrecognized risk factor for mortality among individuals with type 2 diabetes (T2D). This study aimed to evaluate the associations of underweight status with mortality among individuals with T2D.

METHODS

This nationwide, retrospective, population-based cohort study used data from...

🗓️ 2025-12-06
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreUnderweight and Mortality in Type 2 Diabetes: A Nationwide Retrospective Cohort Study.

Air pollution exacerbates cardiovascular-kidney-metabolic syndrome and sarcopenia comorbidity via shared genetic-epigenetic mechanisms: A multi-omics and Mendelian Randomization study.

BACKGROUND

Ambient air pollution aggravates cardiovascular-kidney-metabolic (CKM) disorders and sarcopenia, yet the shared genetic and epigenetic mechanisms that underlie their frequent co-occurrence remain poorly understood.

METHODS

We integrated genome-wide association study (GWAS) data for CKM components (cardiovascular disease [CVD], chronic kidney disease [CKD],...

🗓️ 2025-11-22
📰 Publication: Metabolism-Clinical And Experimental
Read MoreAir pollution exacerbates cardiovascular-kidney-metabolic syndrome and sarcopenia comorbidity via shared genetic-epigenetic mechanisms: A multi-omics and Mendelian Randomization study.

Is Appendicular Lean Soft Tissue Mass a Clinically Valid Diagnostic Marker for Sarcopenia?

AIM

Geriatric experts have long debated the inclusion of appendicular lean soft tissue mass (ALSTM) in the diagnostic criteria for sarcopenia. This study examined whether a diagnostic model for sarcopenia that excludes appendicular lean soft tissue mass (ALSTM) is equivalent to...

🗓️ 2025-11-18
📰 Publication: Geriatrics & Gerontology International
Read MoreIs Appendicular Lean Soft Tissue Mass a Clinically Valid Diagnostic Marker for Sarcopenia?

Integrating genetics and transcriptome analyses identify potential biomarkers and immune interactions in metabolic syndrome-related sarcopenia.

BACKGROUND

Increasing evidence has indicated that metabolic syndrome (MetS) exists in a close link with sarcopenia; however, the potential mechanism and biomarkers between them remain uninvestigated. This study leverages integrative genetics and transcriptome to identify potential biomarkers and immune interactions in...

🗓️ 2025-11-06
Read MoreIntegrating genetics and transcriptome analyses identify potential biomarkers and immune interactions in metabolic syndrome-related sarcopenia.

Irisin, Brain-Derived Neurotrophic Factor (BDNF), and Redox Balance in Geriatric Dynapenia.

Irisin and brain-derived neurotrophic factor (BDNF) are considered potential biomarkers for sarcopenia; however, their interplay and relationship with oxidative stress remain unclear. Therefore, the aim of this study was to assess the serum concentration of irisin and BDNF in patients...

🗓️ 2025-10-29
Read MoreIrisin, Brain-Derived Neurotrophic Factor (BDNF), and Redox Balance in Geriatric Dynapenia.

Prognostic role of sarcopenia in heart failure patients.

AIM

Sarcopenia is common in heart failure (HF) patients; however, there are no data regarding the possible long-term prognostic role of sarcopenia in younger adults with chronic HF without malnutrition. The aim of this study was to examine the long-term prognostic...

🗓️ 2025-10-29
📰 Publication: Cardiovascular Diabetology
Read MorePrognostic role of sarcopenia in heart failure patients.

Overt hepatic encephalopathy after elective and preemptive TIPS: Risk factors and prognosis.

BACKGROUND & AIMS

Overt hepatic encephalopathy (OHE) develops in 30-50% of patients after transjugular intrahepatic portosystemic shunt (TIPS) placement, depending on patient characteristics and TIPS indication. Data on OHE after preemptive TIPS (pTIPS) are limited. We aimed to assess the prevalence...

🗓️ 2025-10-29
📰 Publication: Jhep Reports
Read MoreOvert hepatic encephalopathy after elective and preemptive TIPS: Risk factors and prognosis.

SARCOPENIA DEFINITION

Sarcopenia is a condition which focuses on muscle loss. Loss of muscle mass and function, especially muscle strength and gait speed, associated with aging occurs in sarcopenia. Sarcopenia, cachexia, and malnutrition are considered as the main causes of muscle wasting and affect millions of elderly people and patients. Moreover, muscle atrophy can develop independently from diseases and age through disuse of the muscles. For a better classification and common language in medical science for ‘muscle wasting disease’ there is a proposal to combine the concepts of muscle wasting, sarcopenia, frailty, and cachexia by disease aetiology and disease progression. Patients with muscle atrophy show decreased muscle strength and therefore reduced quality of life, which is caused by a lower activity and increased exercise intolerance.

Despite a large number of studies, the understanding of the development of muscle wasting and the involved pathways remains very limited and more research is needed. Although many researchers and pharmaceutical companies have tried to find therapies for muscle atrophy, including cachexia and sarcopenia, no solution has been established until now.

REFERENCES

Rosenberg IH. Sarcopenia: origins and clinical relevance. Clin Geriatr Med 2011;27:337–339.

Anker SD, Coats AJ, Morley JE, Rosano G, Bernabei R, von Haehling S, Kalantar-Zadeh K. Muscle wasting disease: a proposal for a new disease classification. J Cachexia Sarcopenia Muscle 2014;5:1–3

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!